Does choroidal melanoma regression correlate with chromosome 3 loss after ruthenium brachytherapy?
| Autor: | Bertil Damato, Carl Groenewald, Heinrich Heimann, Patrick J Chiam, Sarah E. Coupland, Helen Kalirai |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Choroidal melanoma
Adult Male Pathology medicine.medical_specialty Monosomy medicine.medical_treatment Plaque removal Brachytherapy Apoptosis Cohort Studies Cellular and Molecular Neuroscience Biopsy medicine Humans Melanoma In Situ Hybridization Fluorescence Aged Retrospective Studies Aged 80 and over medicine.diagnostic_test business.industry Choroid Neoplasms Radiotherapy Dosage Middle Aged medicine.disease Aneuploidy Sensory Systems Ophthalmology Fine-needle aspiration medicine.anatomical_structure Chromosome 3 Female Choroid Chromosomes Human Pair 3 Chromosome Deletion Ruthenium Radioisotopes Nuclear medicine business Multiplex Polymerase Chain Reaction |
| Zdroj: | The British journal of ophthalmology. 98(7) |
| ISSN: | 1468-2079 |
| Popis: | Aim To determine the reduction of choroidal melanoma thickness 6 months after ruthenium 106-brachytherapy according to chromosome 3 status, which correlates strongly with metastatic death. Methods Transscleral fine needle aspiration biopsy was performed prior to the insertion of a radioactive plaque if the tumour was deemed sufficiently thick and anterior for such a procedure. Transretinal biopsy with a 25-gauge vitreous cutter was performed for thin and posterior tumour within a month of plaque removal. The chromosome 3 status was determined by fluorescence in situ hybridisation from 2002 until 2006, and by either multiplex ligation-dependent probe amplification and/or microsatellite analysis after this period until the end of the study. The choroidal melanoma dimensions were obtained from outpatient visits. Results 149 eyes from 149 patients were included. The mean age was 60.8 years. 84 eyes (56.4%) had disomy 3 and 65 eyes (43.6%) monosomy 3. The median pretreatment tumour thickness was 3.0 mm in disomy 3 and 4.1 mm in monosomy 3 tumours (p=0.018). The follow-up duration medians were 6.3 months for disomy 3 and 6.4 months for monosomy 3 tumours (p=0.68). The rates of thickness reduction were 6.7% and 7.0% per month, respectively (p=0.59). Thickness reduction exceeding 50% occurred in 32 (38.1%) disomy 3 and 24 (36.9%) monosomy 3 tumours. Conclusions The rate of choroidal melanoma regression after ruthenium-106 brachytherapy does not appear to correlate with chromosome 3 loss, suggesting that tumour thickness reduction 6 months after treatment is unlikely to predict survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|